1987
Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Dmitrovsky E, Matthews M, Bunn P, Schechter G, Makuch R, Winkler C, Eddy J, Sausville E, Ihde D. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. Journal Of Clinical Oncology 1987, 5: 208-15. PMID: 3492594, DOI: 10.1200/jco.1987.5.2.208.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCytologic transformationCell lymphomaClinical courseClinicopathologic entityCutaneous T-cell lymphoma patientsTumor cell DNA contentT-cell lymphoma patientsAggressive clinical courseDistinct clinicopathologic entityCell lymphoma patientsPeripheral blood smearMalignant T cellsLarge cell lymphomaConvoluted lymphocytesMedian survivalVisceral sitesLymph nodesOccasional patientMedian timeLymphoma patientsPoor prognosisCell DNA contentT cells
1979
Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course
Lipson S, Chretien P, Makuch R, Kenady D, Cohen M. Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course. Cancer 1979, 43: 863-870. PMID: 218717, DOI: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsTotal T cellsPretreatment CEA levelsT cellsCEA levelsClinical courseCellular immunityTumor responsePretreatment levelsCarcinoembryonic antigenAdministration of thymosinIntensive chemotherapy programsPeripheral blood levelsSmall cell carcinomaDuration of responseOverall tumor responseThymus-dependent lymphocytesLarger patient populationType of treatmentP groupMechanism of actionComplete remissionT60 groupChemotherapy programBronchogenic carcinomaImmune defectsEffects of Thymosin Fraction 5 in Cancer Patients: In Vitro Studies and Correlations with Clinical Course in Patients Receiving Thymosin
Chretien P, Lipson S, Makuch R, Kenady D, Snyder J, Cohen M. Effects of Thymosin Fraction 5 in Cancer Patients: In Vitro Studies and Correlations with Clinical Course in Patients Receiving Thymosin. 1979, 159-166. DOI: 10.1016/b978-0-08-023194-5.50023-1.Peer-Reviewed Original ResearchT cell levelsThymosin fraction 5Cancer patientsClinical coursePatient groupT cellsLow CEA levelWeeks of therapyCell-mediated immunityEffect of thymosinSmall cell carcinomaSuch patient groupsComplete tumor remissionFraction 5Certain serum glycoproteinsSimilar groupsAdjuvant treatmentIntensive chemotherapyImmunologic effectsCEA levelsFurther therapyImmune defectsCellular immunityCell carcinomaTumor remission
1978
Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy.
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M, Minna J. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Journal Of The National Cancer Institute 1978, 62: 1787-90. PMID: 215307.Peer-Reviewed Original Research